Table 2.

Predictors of 30-d mortality among patients with Pseudomonas aeruginosa bloodstream infection (n = 6,714) with and without adjustment for COVID-19 coinfection

	Logistic regression				Modified Poisson
	Unadjusted OR	95% CI	Adjusted OR	95% CI	Unadjusted RR	95% CI	Adjusted RR	95% CI
COVID-19 coinfection	NA	NA	2.15	1.26–3.68	NA	NA	1.44	1.01–2.06
Period
COVID-19 period	Reference
Early pre-COVID-19 period	0.85	0.72–0.99	0.89	0.76–1.05	0.91	0.80-1.03	0.94	0.82–1.07
Late pre-COVID-19 period	0.78	0.64–0.94	0.82	0.67–1.00	0.86	0.73–1.00	0.88	0.75–1.04
Sex
Female	Reference
Male	0.83	0.56–1.23	0.83	0.56–1.23	0.90	0.66–1.22	0.90	0.66–1.22
Age
Age in decades over 40	1.07	1.01–1.13	1.07	1.02–1.13	1.04	1.00–1.09	1.04	1.00–1.09
Race
White	Reference
Black	1.03	0.88–1.20	1.03	0.88–1.20	1.02	0.91–1.15	1.02	0.91–1.14
Other	0.72	0.40–1.29	0.73	0.40–1.30	0.82	0.52–1.30	0.83	0.52–1.31
Ethnicity
Non-Hispanic/Latino	Reference
Hispanic/Latino	1.02	0.82–1.27	1.02	0.82–1.27	1.01	0.86–1.20	1.01	0.85–1.20
Charlson Comorbidity Index
0–2	Reference
3–5	1.45	1.23–1.72	1.45	1.23–1.72	1.29	1.13–1.49	1.29	1.13–1.49
6+	2.11	1.78–2.50	2.11	1.78–2.50	1.62	1.41–1.86	1.62	1.41–1.86
Modified APACHE score
<50	Reference
50–59	2.37	1.91–2.95	2.36	1.90–2.93	2.15	1.76–2.63	2.15	1.76–2.62
60–74	4.26	3.48–5.22	4.25	3.47–5.20	3.35	2.79–4.02	3.34	2.79–4.02
75–84	10.89	8.40–14.13	10.89	8.39–14.13	5.77	4.69–7.08	5.76	4.69–7.07
85+	22.13	16.78–29.19	21.95	16.63–28.96	7.59	6.24–9.23	7.53	6.19–9.16
Missing	7.52	6.22–9.08	7.48	6.19–9.04	4.80	4.06–5.68	4.79	4.05–5.66
Treatment administered within 48 h
Targeted treatment	Reference
No targeted treatment	1.84	1.59–2.13	1.84	1.59–2.13	1.43	1.29–1.60	1.43	1.28–1.60

Note. OR, odds ratio; CI, confidence interval; RR, relative risk.